All In Biotech

Drug Trial Radar · NCT04581512

Study to Evaluate the Safety and Tolerability of EP0042

A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Nov 2, 2020

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Ellipses PharmaIndustry
Sponsor type
Industry
First posted
Oct 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

Conditions

  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndromes

Interventions

  • EP0042Drug

    EP0042 Oral 20 mg 50 mg capsules

  • VenetoclaxDrug

    Venetoclax

  • Azacitidine (AZA)Drug

    Azacitidine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period.Time frame: First cycle of treatment (28 Days)

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Royal Perth Hospital

    Perth, Western Australia, Australia · Recruiting

  • Amsterdam UMC

    Amsterdam, Netherlands · Recruiting

  • Erasmus MC

    Rotterdam, Netherlands · Recruiting

  • University College London Hospital

    London, United Kingdom · Recruiting

  • The Christie Hospital

    Manchester, United Kingdom · Recruiting

  • The Royal Marsden

    London, UK, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.